News | June 11, 2008

Cook's Drug-Eluting Peripheral Stent Shows Promising Preliminary Results

June 12, 2008 – The registry arm of a clinical study to assess the safety and effectiveness of Cook Medical’s Zilver PTX Drug-Eluting Peripheral Stent (DES) in treating peripheral arterial disease (PAD) has yielded positive interim results, trial investigators reported at the 2008 SVS Vascular Annual Meeting last week.

The findings, presented by Michael Dake, M.D., professor of Radiology, Internal Medicine and Surgery and chairman of the Department of Radiology at the University of Virginia Health System, reveal clinical improvement, excellent stent durability (i.e., fracture resistance), high rates of event-free survival (EFS) and freedom from target lesion revascularization (TLR). This preliminary information suggests no safety concerns, and promising effectiveness results.

“Cook's registry study and randomized trial are the first to use a paclitaxel-coated stent in the treatment of arterial blockages outside the heart,” said Dr. Dake, the trial’s global principal investigator. “They are designed to evaluate the safety and effectiveness of DES technology versus percutaneous transluminal angioplasty, and our initial findings in the registry arm give us every reason to believe that Zilver PTX may have the integrity, safety and durability needed to successfully address many of the well-known limitations of angioplasty alone for management of PAD.”

Interim data were compiled at six and 12 months for 435 patients and 200 patients respectively from the registry study, which enrolled a broad spectrum of patients, including those with complex lesions (e.g., long lesions, total occlusions, in-stent restenosis). The corresponding EFS rates were 94 percent and 84 percent, and freedom from TLR was 96 percent and 88 percent. Clinical measures that included ankle-brachial index, Rutherford score, and walking distance and speed scores showed significant improvement at six months and was maintained through 12 months.

Evaluation of stent x-rays is ongoing, and currently suggests stent fractures in only about one percent of cases at six months and less than two percent of cases at 12 months. Follow-up in the registry arm of the study will continue through two years.

“We are quite pleased with this first round of data from the registry portion of the study, and are optimistic we’ll encounter similar results throughout the duration of the Zilver PTX trial,” said Rob Lyles, global leader of Cook Medical's Peripheral Intervention products division. “At Cook, we are continually driving to improve the quality of our products and, in turn, improve the quality of patient outcomes. We are particularly excited about the potential benefits our self-expanding Zilver PTX stent provide can patients suffering from PAD.”

The clinical study is designed to evaluate the Zilver PTX in more than 1,000 patients across 89 trial sites in the United States, Asia, Latin America, Canada and Europe. In addition to the 790 DES patients enrolled in the registry arm of the study, approximately 240 of the 480 patients to be enrolled in the randomized arm of the study will receive the DES. Follow-up is ongoing for the registry, while enrollment in the randomized study is expected to be complete within the coming months.

For more information, visit and

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init